Piperacillin (T-1220) is a new semisynthetic penicillin with an unusually broad spectrum of antimicrobial activity. In vitro comparisons of this drug with 6 other beta-lactam antimicrobics (ticarcillin, carbenicillin, ampicillin, cephalothin, cefamandole and cefoxitin) were conducted. These included minimal inhibitory concentrations (MIC) against 394 bacterial isolates, the minimal lethal concentrations (MLC) against 79 of those, as well as the effect of inoculum size on the MIC and MLC of the drugs. Piperacillin had significantly greater activity than did the other penicillins against Pseudomonas species and Klebsiella pneumoniae. Against P. aeruginosa piperacillin was 8-and 16-fold more active than ticarcillin and carbenicillin, respectively. The MLC of piperacillin rarely differed from the MIC by more than one loge dilutions except against P. aeruginosa in which the MLC was 4-fold greater or more than the MIC of 45% of isolates tested. Ticarcillin, carbenicillin and cefoxitin showed minimal inoculum size effects. Cefamandole results showed the greatest inoculum size variation with 55 % and 37 % of isolates showing an 8-fold increase in MIC and MLC respectively by increasing inoculum from 105 to 107 CFU/ml. Piperacillin was intermediately effected having 25% of strains > 8-fold increase in MIC.
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A total of 394 bacterial isolates were contributed by the collaborating laboratories for this study. Most of the isolates were tested in duplicate by two of the collaborating laboratories (Center for Disease Control and the Sacramento Medical Center) in a manner previously reported.1,2 A third laboratory, Kaiser Foundation, also tested a more limited number (MLCs and inoculum size studies).
No significant variation in MIC results were encountered between these participating laboratories.
Antimicrobic Susceptibility Testing:
Minimum inhibitory concentrations (MICs) were determined by the broth microdilution method.
MUELLER-HINTON broth was commercially dispensed in a single lot of plastic trays (Micro Media Systems, San Jose, California) and distributed to the testing laboratories. The trays were stored at -60 C until inoculated . Prior to use the trays were thawed at room temperature (approximately 20-30 minutes) and inoculated with disposable inoculators delivering 5 ul to each well.
At all three laboratories, a logarithmic phase broth culture was diluted to match the turbidity of a 0.5 MAcFARLAND standard. The suspension was then diluted 1 : 50 in sterile water containing 0.02 Tween 80 and dispensed as described earlier. Final inoculum achieved was 1 x 105 colony forming units (CFU) per ml. For the testing of the fastidious streptococci including S. pyogeues and S. pneumoniae, the inoculum was standardized in MUELLER-HINTON broth containing 5 % lysed rabbit blood and 0.1 ml of this adjusted cell suspension was added to each microdilution well, giving a final concentration of 1 x 105 CFU/ml.
The MIC was recorded as the lowest concentration totally inhibiting bacterial growth (clear well), after approximately 18 hours of incubation at 35°C in a forced air incubator. Occasionally, visible growth occurred in concentrations I -2 wells above the MIC (the skipped-tube phenomenon).
Minimum lethal concentrations were determined for 79 organisms from seven genera by subculturing 5 /rl from each microdilution well. The 5 /tl subcultures were transferred to trypticase soy agar with 5%) sheep blood. The subcultures were made with multiple inocul un replicator onto a 150 x 100 nom plate. After 48 hours of incubation, the endpoints were read as the lowest concentration yielding no more than 0.1 % survivors (99.9 % kill). DEC. 1977 1rvdroplrila to the seven antimicrobics with cefamandole and piperacillin being most active.
Among the 108 Ps. aeruginosa isolates tested, several strains were resistant (>8ltg!ml) to gentamicin and/or tobramycin. These 14 isolates and the sensitive strains of Ps. aeruginosa are shown in (12) , Proteus retteeri (9), Proteus vuharis (6).
MIC-MLC Comparisons
The MLC/MIC ratios for piperacillin, ticarcillin and carbenicillin are shown in a. Sensitive is = or less than 4 pg/ml to both aminoglycosides tested in cation supplement MUELLER-HIXTON broth.
Inoculum Size MIC-MLC Comparisons
The effects of inoculum size on MIC and MLC results were studied on 79 organisms at 103, 105, and 107 colony forming units/ml (Table 6 ). Only those organisms (listed in Table 5 ) not having off-scale MIC values were tabulated. Lower numbers of cefamandole MIC and MLC were noted due to a large incidence of <0.51tg/ml MIC-MLC values among the Enterobacteriaceae in addition to > 256,ug/ml MIC-MLC against Ps.
aeruginosa, Serratia and some Proteus species.
Ticarcillin, carbenicillin and cefoxitin showed minimal variation (increase) in MIC or MLC when the inoculum was raised from 103 to 105 CFU/ml and 105 to 107 CFU/ml. Ninety-two to 100% of the endpoints were <3 log2 dilutions.
Piperacillin was similar to the above agents at 103 -105 CFU/ml, but had 24-25 % of MIC-MLC results markedly altered (> 8-fold increase)
by inoculum increases to 107 CFU/ml. Nearly all isolates having piperacillin susceptibility inoculum effect were Klebsiella pneurnoniae (mean MIC-MLC increase= 64-fold). Cefamandole MICs and MLCs were markedly increased by raising inoculum Table 5 . MIC-MLC comparison of piperacillin, carbenicillin and ticarcillin for 79 organisms @ 105 CFU/ml inoculum size.
Organism (#)
E. coli (10) Klebsiella pneumoniae (10) Enterobacter speciesa (10) Proteus mirabilis (10) lndole-positive Protein speciesb (10) Serratia marcescens (10) Pseudomonas aeruginosa (9) Staphylococcus aureus ( Piperacillin (T-1220) belongs to the semisynthetic group of penicillins and is structurally similar to ampicillin. More extensive a-substitutions have provided this compound with a broad antimicrobial spectrum that includes gram-positive and gram-negative bacteria, especially Pseudomonas, Klebsiella, Serratia, Proteus and Enterococci. The compound is poorly absorbed orally, but high serum concentrations are achieved by parenteral routes.
Other new semisynthetic penicillins that most resemble piperacillin are BL-P1654 (Bristol), PC-904 (Sumitomo) and pirbenicillin (CP-33,994-2, Pfizer). All of these antimicrobics have antipseudomonas activity 8-to 16-fold that of carbenicillin8-10). However, each has one or more disadvantages when compared to piperacillin. BL-P1654 is adversely affected by both serum and increased inoculum concentrations, has a limited spectrum versus all Proteus species and lastly is toxic to some animal species').
PC-904 also is less active than piperacillin against Proteus mirabilis, the indole-positive Proteus species and Serratia species9). Like PC-904, pirbenicillin has little activity on Proteus species and is significantly more protein bound than piperacillin10). Piperacillin compared to carbenicillin and ticarcillin had a wider antimicrobial spectrum and increased activity, particularly against Pseudomonas species, Serratia and Klebsiella pneumoniae. Like the new cephalosporins, piperacillin showed excellent inhibitory activity against Enterobacter species and indole-positive Proteus species, while adding the Enterococci, Serratia species, and K. pneumoniae to its spectrum. Only ampicillin was superior to piperacillin against S. faecalis.
The only apparent drawbacks to piperacillin were the slight inoculum size effects on MIC and MLCs at 10' CFU/ml levels, particularly among K. pneumoniae isolates. Also piperacillin is susceptible to beta-lactamase activity similar to carbenicillin, ticarcillin and ampicillin. These features may limit its efficacy against beta-] actamase-producing S. aureus, H. influenzae, N. gonorrhoeae and some populations of Enterobacteriaceae including E. coli.
The combination of excellent in vitro inhibiting effects on a wide spectrum of bacteria and in vivo pharmacology makes piperacillin (T-1220) a very promising parenteral antimicrobic. If dosages were used permitting piperacillin serum levels of 64 /cg/ml, this would inhibit 96 % of the gram-positive and negative organisms in a clinical isolate study of 10,858 strains12). Ninety-one percent would be covered by concentrations of 16 pg/ml. These in vitro data coupled with a 22 serum protein binding, active urinary excretion (66%), high biliary concentrations, favorable human pharmacokinetics, and effective treatment of experimental animal infection favors further human in vivo investigations. Additional in vitro studies on anaerobic bacteria are also needed.
